assess-pharmacogenomic-evidence
SolidAssesses whether pharmacogenomic covariate effects are characterised across the programme's evidence base — in-vitro enzyme and transporter genotype data, PopPK covariate analyses, dedicated PGx sub-studies, and the labelling concept — producing a gene-enzyme-phenotype register in which every stated PGx effect traces to its source and every source-identified polymorphism traces to its downstream statement. Use this skill when someone asks whether pharmacogenomic effects are characterised for a compound, whether a PopPK analysis covers the relevant polymorphisms, or what PGx gaps remain. Example: "Please pharmacogenomic effects are characterised for a compound." Do not use for demographic covariates (age, sex, body size), for organ-impairment characterisation, for drug-drug interaction assessment, or for any request to recommend a genotype-based dose adjustment.
Install
Quality Score: 84/100
Skill Content
Details
- Author
- malekokour
- Repository
- malekokour/clinpharm-pmx-skills
- Created
- 1 weeks ago
- Last Updated
- 6 days ago
- Language
- Python
- License
- MIT
Similar Skills
Semantically similar based on skill content — not just same category
assess-demographic-covariate-effects
Assesses whether age, sex and body-size covariate effects on exposure are characterised, internally consistent, and traceable to their sources — the PopPK covariate analysis, any dedicated sub-study, the factor-coverage matrix and the labelling concept — and flags effects that are stated without a source, sourced but unstated, or stated inconsistently across documents. Use this skill when someone asks whether demographic covariates are adequately characterised for a programme, whether the age, weight or sex effects in a PopPK report match what the label says, or what demographic gaps remain before filing. Example: "Are age, weight and sex effects characterised for this compound?" Do not use for pharmacogenomic covariates, for renal or hepatic impairment, for drug-drug interactions, for selecting or adjusting a dose, or for any request to decide whether a covariate effect is clinically meaningful.
assess-special-population-strategy
Assesses the completeness and internal consistency of a programme's special-population evidence strategy — renal impairment, hepatic impairment, paediatrics, pregnancy and lactation, elderly, and other defined sub-populations — against the programme's declared scope, the target product profile, and the guidance-anchored criteria that create study or analysis obligations for each population. Use this skill when someone asks whether the special-population strategy covers what a reviewer will expect, which populations still need characterisation, or whether the strategy documents are internally consistent. Example: "Please the special-population strategy covers what a reviewer will expect, which populations still need characterisation." Do not use for reviewing one organ-impairment study report, for demographic covariate assessment in a PopPK, for pharmacogenomic characterisation, or for any request to decide whether a waiver rationale is sufficient or to commit to a study.
assess-development-plan-gaps
Assesses a clinical pharmacology development plan against guidance-anchored evidence expectations, classifying every expected element as present, triggered, waivable-with-rationale, or a residual gap, each traced to the criterion that creates the obligation. Use this skill when someone asks what clinical pharmacology evidence a programme is still missing, whether a plan covers what a reviewer will expect, or which studies the drug's own properties have made obligatory — for example "what CP work are we still missing before the pre-NDA meeting" or "does this plan cover the renal and hepatic expectations". Do not use for reviewing one interaction package, for assembling agency-facing briefing content, or for any request to decide whether a gap is acceptable, to commit to a study, or to approve a plan.